Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.

Alberto Ortiz,Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano,Beatriz Fernández-Fernández,Francisco Martínez Debén,Juan Diego Mediavilla,Alfredo Michan-Doña,Maria Jose Soler,Jose Luis Gorriz

Expert review of clinical pharmacology（2023）

引用 0|浏览5

暂无评分

摘要

As finerenone increases potassium levels in a predictable way, patients at risk of hyperkalemia can be identified early in clinical practice and monitored for an easy management. This will allow people with T2DM and CKD to safely benefit from improved cardiorenal outcomes.

查看译文

关键词

Cardiovascular, chronic kidney disease, finerenone, hyperkalemia, potassium, kidney outcomes, type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要